Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of anlotinib in patients with stage IV extranodal natural killer/T-cell lymphoma, nasal type.


Clinical Trial Description

Extranodal natural killer/T-cell lymphoma (ENKTCL), nasal type, is a rare subtype of non-Hodgkin lymphoma (NHL) with relatively high incidence in China. L-asparaginase based chemotherapy improved overall response and prolonged the long-term survival for patients with stage IV. But the treatment for the patients with advanced disease and resistant to L-asparaginase based chemotherapy has not been established. The overall survival for these patients are very poor. This study is designed to evaluate the efficacy and safety of anlotinib in patients with stage IV ENKTCL and refractory to L-asparaginase based chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03618238
Study type Interventional
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status Completed
Phase Phase 2
Start date July 25, 2018
Completion date April 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT05058755 - Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma N/A
Recruiting NCT06314334 - Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma Phase 2
Recruiting NCT04004572 - Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma Phase 2
Recruiting NCT03623087 - SIMPLE Chemotherapy for NK Lymphoma/Leukaemia Phase 3
Recruiting NCT03107962 - Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma Phase 2
Recruiting NCT03630731 - Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma Phase 2
Completed NCT03936452 - Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma Phase 2
Recruiting NCT04366128 - Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL N/A
Recruiting NCT06376721 - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Phase 1/Phase 2